Viosera Therapeutics

Viosera Therapeutics was a computational biotech company founded in 2016 and headquartered in St. Louis, Missouri, focused on predicting and overcoming drug resistance in cancer and bacterial infections. The company combined computational biology and machine learning to identify mechanisms of resistance before they emerge clinically, enabling the design of more durable treatment regimens. Viosera participated in Y Combinator's Winter 2019 batch and was co-founded by researchers from Washington University in St. Louis. Its website is no longer active, and the founding team subsequently pivoted to a related venture called resistanceBio; the company appears to be defunct or absorbed.